Although the molecular mechanisms of MM pathogenesis are not well understood, many biomarkers for MM progression have been described, including CTAG2, MAGEA6, CCND2, NEK2, and E2F2, some of which could predict clinical prognosis and therapeutic effectiveness [6]. Here, NEK2 is linked to Miyoshi myopathy.